Journal
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Volume 18, Issue 2, Pages E143-E146Publisher
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clml.2017.12.008
Keywords
Anti-PD-1; Autoimmune diabetes; Human immunodeficiency virus; Immune checkpoint inhibitor; Immune-related adverse event
Categories
Funding
- National Institutes of Health [1R01 CA206479-01, T32 CA174647]
- VA Health Services Research and Development Center of Innovation grant [CIN 13-413]
Ask authors/readers for more resources
We present a case of a veteran with well-controlled human immunodeficiency virus (HIV) infection and primary refractory classical Hodgkin lymphoma (HL) who, after multiple prior lines of therapy, received nivolumab with a complete response. He also developed autoimmune diabetes mellitus after 6 months of nivolumab. HIV-associated HL is currently treated under the same algorithm as HL in the general population, but its unique biology, particularly the near-universal association with Epstein-Barr virus, regardless of histology, suggests that immunotherapy may have an important role in the management of this disease. Most clinical trials highlighting checkpoint inhibitors have excluded HIV-infected patients. More prospective data is clearly needed to delineate the risks and benefits of immunotherapy in this population with increased autoimmunity at baseline.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available